DADC
ARLZ

D.A. Davidson & Co’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

D.A. Davidson & Co’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed – – 2388
2017
Q2 		$0 Hold
200
– – ﹤0.01% 2520
2017
Q1 		$0 Hold
200
– – ﹤0.01% 2621
2016
Q4 		$0 Hold
200
– – ﹤0.01% 2601
2016
Q3 		$0 Hold
200
– – ﹤0.01% 2589
2016
Q2 		$0 Buy
+200
New +$755 ﹤0.01% 2489

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

D.A. Davidson & Co's ARLZ Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2017, closing a stake of 200 shares.

D.A. Davidson & Co first reported a position in ARLZ in Q2 2016 and held it in 5 quarters. The position peaked at $0 in Q2 2017. 59 funds tracked by Wall St. Rank hold ARLZ as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 200 Aralez Pharmaceuticals Inc. shares in Q3 2017.
  • D.A. Davidson & Co first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 5 quarters.
  • D.A. Davidson & Co's Aralez Pharmaceuticals Inc. position peaked at $0 in Q2 2017.
  • 59 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.